Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L19IL2/L19TNF Intratumoral Therapy in Skin Cancers
2024-518531-10-00Phase 2Authorised
- Sponsor
- Philogen
- Start
- Nov 2024
- Modality
- Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of onfekafusp alfa and darleukin in basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (cSCC), Merkel cell carcinoma (MCC) and 4 more, sponsored by Philogen. Primary endpoint: Confirmed best overall response rate (BORR). Planned start Nov 2024; status: authorised.
02
Drugs
onfekafusp alfadarleukin
03
Conditions
basal cell carcinoma (BCC)cutaneous squamous cell carcinoma (cSCC)Merkel cell carcinoma (MCC)keratoacanthoma (KA)malignant adnexal neoplasm
Beyond the preview
Go deeper on 2024-518531-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518531-10-00.